Authors
Latest:
Anticipating Key Studies and Pipeline Treatments in mCRC LandscapeThe experts provide their final thoughts surrounding the impact of prospective trials and therapy regimens for treating patients with refractory mCRC.
Latest:
Dr. Scott Rowley on Allogeneic Stem Cell TransplantScott Rowley, MD, the Chief of John Theurer Cancer Center's Blood and Marrow Stem Cell Transplantation Division, discusses the challenges of allogeneic stem cell transplant.
Latest:
Dr. Samuelson on the Comorbidities that Affect Treatment Decisions in Prostate CancerScott Samuelson, MD, medical oncologist at Utah Cancer Specialists, discusses the comorbidities that may affect treatment decisions for patients with metastatic prostate cancer.
Latest:
Dr Tagawa on the Rationale for Investigating First-Line Nivolumab Plus Cisplatin in Urothelial CancerScott T. Tagawa, MD, MS, FACP, FASCO, discusses the rationale for evaluating nivolumab plus cisplatin-based chemotherapy in first-line urothelial cancer.
Latest:
Prostate Cancer Management: Future Directions in CareClosing out their discussion on the management of prostate cancer, panelists consider remaining unmet needs and future directions in care.
Latest:
Dr. Kim Discusses Minimally Invasive Surgery and Laparotomic Surgery in Cervical CancerSe Ik Kim, MD, research fellow, Department of Obstetrics and Gynecology, Seoul National University Hospital, discusses the use of minimally invasive surgery and laparotomic surgery in patients with cervical cancer.
Latest:
Automating the Documentation and Coding ProcessAccurate documentation and coding is essential for efficient billing and reimbursement.
Latest:
Dr. Dowdy on the Association of Molecular Subtypes and Responses to Bevacizumab in Ovarian CancerSean C. Dowdy, MD, discusses the association of molecular subtypes and responses to bevacizumab in ovarian cancer.
Latest:
Ovarian Cancer Subtypes May Predict Response to BevacizumabSean Dowdy, MD, a Mayo Clinic gynecologic oncologist discusses a study showing molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has found.
Latest:
Dr. Grimm on the Brain Cancer Predictive Marker MGMTDr. Sean Grimm from Northwestern University, Feinberg School of Medicine on MGMT as a Predictive Marker in Brain Cancer
Latest:
Coping With Burnout? Tips on Handling This Occupational HazardBurnout is described as a syndrome of "emotional exhaustion, depersonalization, and feelings of low personal accomplishment," and is an increasingly problematic condition among physicians for a multitude of reasons.
Latest:
Dr. Szeja on Adjuvant Radiation Therapy After Lumpectomy in Elderly Patients With TNBCSean Szeja, MD, radiation oncologist, University of Texas Medical Branch, discusses outcomes associated with adjuvant radiation therapy following lumpectomy for elderly patients with triple-negative breast cancer.
Latest:
Different Faces of a Career in OncologyAt various stages of our lives, most of us experience situations or events that help us to mature and may lead to decisions that affect our futures. Two such events in my life forged my career choice as a communitybased oncologist.
Latest:
Adjuvant Therapy for Non-Small Cell Lung Cancer: Impact of Recent Clinical Trials on Community PracticeNon-small cell lung cancer (NSCLC) is diagnosed at an early stage, when it is amenable to surgical resection in approximately 20% to 25% of cases.
Latest:
Dr. Stuart on Risks of Phase I Liver Dysfunction StudiesSelena Juarez Stuart, MD, hematology/oncology fellow, Cancer Therapy & Research Center, The University of Texas Health Science Center at San Antonio, discusses the risks and benefits of phase I liver dysfunction studies.
Latest:
Challenges in the Treatment of Patients With MCLSelina Chen-Kiang, PhD, professor of pathology and immunology, Weill Cornell Medicine, discusses challenges in the treatment of patients with mantle cell lymphoma (MCL).
Latest:
Dr Giralt on Determining Transplant Eligibility in MDSSergio A. Giralt, MD, discusses how to determine transplant eligibility and the evolving role of transplant for patients with myelodysplastic syndromes.
Latest:
VOD: Ensuring Best OutcomesExperts share tips for treating patients with VOD with defibrotide, including strategies to ensure best possible outcomes.
Latest:
Phase II Clinical Trial of Intratumoral Dendritic Cells Injections and Neoadjuvant Radiotherapy in Resectable Soft Tissue SarcomasNeoadjuvant radiation with dendritic cell injections has the potential to be safe, effective, and immunogenic in high-grade soft tissue sarcoma and needs to be confirmed in randomized larger clinical trials.
Latest:
Dr. Berk on Immunotherapy Options for Patients With Colon CancerSeth Berk, MD, section chief of gastrointestinal hematology/oncology at Virtua Memorial Hospital, discusses the use of immunotherapy in colon cancer.
Latest:
Dr. Pollack on the Future Treatment Landscape for SarcomaSeth M. Pollack, assistant professor, Division of Oncology, University of Washington, and attending physician, Seattle Cancer Care Alliance, discusses the future treatment paradigm of soft tissue sarcoma.
Latest:
Dr. Choi on Considering Factors for RT in Prostate CancerSeungtaek L. Choi, MD, an assistant professor in the Department of Radiation Oncology, and clinical Medical Director, Department of Genitourinary Medical Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, discusses the considering factors for patients to receive radiation therapy (RT) for their prostate cancer.
Latest:
Building Upon ScaffoldsCancer care is changing rapidly, and understanding and incorporating new practices is challenging both for practicing oncologists and oncology trainees.
Latest:
Phase II Clinical Trial of Intratumoral Dendritic Cells Injections and Neoadjuvant Radiotherapy in Resectable Soft Tissue SarcomasNeoadjuvant radiation with dendritic cell injections has the potential to be safe, effective, and immunogenic in high-grade soft tissue sarcoma and needs to be confirmed in randomized larger clinical trials.
Latest:
Dr. Kumar on Updated Data from the MAIA Trial in Newly Diagnosed Multiple MyelomaShaji Kumar, MD, discusses the updated data from the phase 3 MAIA trial in newly diagnosed multiple myeloma.
